Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 62.5%Moderate 0 · 0%High 2 · 25%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Lamotrigine plus ASMs vs placebo plus ASMs · Number of participants with adverse events leading to study discontinuation
  Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
  RR 0.49 [0.13, 1.82]
  1 study · 169 participants
  Low
Direct match · question page
- Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs vs placebo plus ASMs · Number of participants with adverse events leading to study discontinuation
  Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
  RR 6.62 [1.56, 28.15]
  2 studies · 396 participants
  High
Direct match · question page
- Rufinamide plus ASMs vs placebo plus ASMs · Number of participants with adverse events leading to study discontinuation
  Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
  RR 4.14 [0.49, 34.86]
  1 study · 59 participants
  Low
Direct match · question page
- Topiramate plus ASMs vs placebo plus ASMs · Number of participants with adverse events leading to study discontinuation
  Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 98 participants
  Low
Direct match · question page
- Clobazam (low, medium and high doses) plus ASMs vs placebo plus ASMs · Number of participants with adverse events leading to study discontinuation
  Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
  RR 4.12 [1.01, 16.87]
  1 study · 238 participants
  High

Clobazam (low, medium and high doses) plus ASMs vs placebo plus ASMs

Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age

Clobazam (low, medium and high doses) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
RR 4.12 [1.01, 16.87]
1 study · 238 participants
High

Felbamate plus ASMs vs placebo plus ASMs

Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age

Felbamate plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
RR 0.97 [0.06, 14.97]
1 study · 73 participants
Low

Lamotrigine plus ASMs vs placebo plus ASMs

Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age

Lamotrigine plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
RR 0.49 [0.13, 1.82]
1 study · 169 participants
Low

Rufinamide plus ASMs vs placebo plus ASMs

Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age

Rufinamide plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
RR 4.14 [0.49, 34.86]
1 study · 59 participants
Low

Topiramate plus ASMs vs placebo plus ASMs

Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 98 participants
Low

Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs vs placebo plus ASMs

Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age

Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
RR 6.62 [1.56, 28.15]
2 studies · 396 participants
High

Cinromide plus ASMs vs placebo plus ASMs

Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rufinamide plus ASMs vs other ASM plus ASMs

Number of adverse events requiring discontinuation of treatment ‐ not reported · Lennox‐Gastaut syndrome, any age

Rufinamide plus ASMs showed no clear difference in number of participants with treatment‐emergent adverse events… compared with other ASM plus ASMs (low certainty).

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
RR 0.96 [0.1, 9.57]
1 study · 37 participants
Low